Azopharma Product Development Group, Inc. has added new equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, FL. The company added the MG Futura Capsule Filler and Bausch & Strobel Aseptic Filling Isolator, new in the powder filling process. These additions support the company’s Xcelodose powder micro-dosing system. The new equipment is part of Azopharma’s recent manufacturing expansion, which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products.
   
The MG Futura, equipped with a standard powder-dosing unit, has the ability to dose two different pellets into a single capsule and is capable of production levels of 6,000/12,000/24,000 and 48,000 capsules per hour. The machine can also perform overencapsulation for use in blinded clinical studies. The B&S Aseptic Filling Isolator provides containment and aseptic isolation during the powder filling operation as well as low humidity conditions. The isolator will also be a key component of Azopharma’s cytotoxic and potent compound production activities, according to the company.
   
Phil Meeks, chief executive officer of Azopharma, said, “The addition of these two pieces of equipment compliment our comprehensive formulation capabilities for all dosage forms and expands our ability to manufacture tablets, capsules and powders.”